NCT06748209|RecruitingPhase 4FDA Device
Establishing Mobile Transcranial Magnetic Stimulation
TMS
Portable Transcranial Magnetic Stimulation (TMS) in a Van for Treatment-Resistant Depression
Loading search results
Sponsor study identifier
interventional
30
1 country
1
Study Start
May 10, 2025
Actual (reported)Primary Completion
March 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 19, 2024
Actual (reported)December 27, 2024
Actual (reported)May 10, 2025
Actual (reported)March 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percent of depression responders
Number of patients with \>50% improvement in Phq-9 scores before and then after 5 days of treatment
From baseline to 1 week immediately after treatment week
Improvement in Depression Symptoms
Change in Phq-9 ratings from baseline to end of treatment
From baseline to 1 week immediately after treatment week
This will be FDA approved Left Prefrontal TMS for treating depression, we will be performing this within a VA, located at clinics throughout SC.
FDA cleared TMS
This is FDA approved TMS
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Medical Univerity of South Carolina
Charleston, South Carolina, 29425, United States
Mark George, MD
Medical University of South Carolina
First Submitted
December 19, 2024
First Posted
December 27, 2024
Study Start
May 10, 2025
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
March 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 6, 2026
Record last verified: 2026-05
age, gender, degree of treatment resistance, current medications, changes in depression scores
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: